March 20, 2001

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655

PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com

FOR IMMEDIATE RELEASE

ZOLL Announces M Series Direct Connectivity to GE's Catalyst MUSE Cardiology Information System

Tuesday, March 20, 2001 – Burlington, MA (March 20, 2001) – ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices which provide pacing and defibrillation, today announced an enhancement to its M Series defibrillators that will allow communication directly with the GE Medical Systems Information Technologies’ Catalyst MUSE cardiology information system. More than 85 % of the 50 leading cardiology hospitals in the United States as ranked by U.S. News and World Report (July 1997), and extensive numbers of hospitals worldwide utilize GE’s Catalyst MUSE system for their cardiology information management needs.

Richard Packer, President and CEO of ZOLL Medical Corporation noted, “The addition of the Catalyst MUSE Interface will further strengthen the M Series family of defibrillators. ZOLL Medical will provide direct communication of pre-hospital 12-lead ECG data into the GE’s family of Catalyst cardiovascular information systems. We believe this communication capability will offer an enormous advantage to our customers in providing quality healthcare to their patients.”

Wayne Reval, ZOLL Marketing Director for EMS, added “The M Series defibrillator will communicate patient ECG data collected in the field directly to the hospital’s Catalyst MUSE system, enabling physicians to quickly view and compare the pre-hospital 12-lead ECG with previous patient ECG records. By detecting clinically significant changes in the ECG, physicians can identify and provide rapid treatment of patients with Acute Myocardial Infarction, commonly known as heart attack. This direct connection from the ZOLL M Series defibrillator will facilitate the transfer of ECG data and eliminate the need for a dedicated receiving station or gateway.”

Adam Miller, GE’s Global General Manager for Cardiology Systems added, “Central to GE’s strategy in Cardiology is facilitating the movement of patient information in the pre-hospital and hospital environments to enhance the quality of patient care. ZOLL’s M Series interface to GE’s Catalyst MUSE will strengthen the connectivity offerings for our respective customers and is a further example of our commitment to work with leading-edge companies like ZOLL.”

ZOLL Medical Corporation designs, manufactures and markets an integrated line of proprietary non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation – pacing and defibrillation – these products are essential in the emergency treatment of cardiac arrest victims both inside and outside the hospital. ZOLL also designs and markets software, which automates collection and management of both clinical and non-clinical data for emergency medical service providers.

GE Medical Systems Information Technologies is a global leader in providing solutions for the reliable and efficient acquisition, analysis and management of patient data in healthcare facilities around the world. The company's offerings include cardiology, patient monitoring, image management, clinical information systems and performance management services. Information Technologies is a GE Medical Systems Company with global headquarters in Milwaukee, Wis.

GE Medical Systems is a $7 billion global leader in medical technology and services. Additional information about GE Medical Systems can be found on the company's Web site at gemedicalsystems.com.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. The Company’s actual results could differ materially from those set forth in the forward-looking statements. Certain factors that might cause such a difference may be discussed in the section entitled “Certain Factors Affecting Future Operating Results” in the Company’s most recent reports filed with the SEC.

News Room Resources

March 20, 2001

Related Info